CLINICAL TRIALS PROFILE FOR NIMODIPINE
✉ Email this page to a colleague
All Clinical Trials for Nimodipine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000280 ↗ | Glutaminergic Agents for Cocaine Abuse - 5 | Completed | National Institute on Drug Abuse (NIDA) | Phase 1 | 1994-09-01 | The purpose of this study is to evaluate glutaminergic agents for cocaine abuse. |
| NCT00000280 ↗ | Glutaminergic Agents for Cocaine Abuse - 5 | Completed | VA Connecticut Healthcare System | Phase 1 | 1994-09-01 | The purpose of this study is to evaluate glutaminergic agents for cocaine abuse. |
| NCT00000280 ↗ | Glutaminergic Agents for Cocaine Abuse - 5 | Completed | Yale University | Phase 1 | 1994-09-01 | The purpose of this study is to evaluate glutaminergic agents for cocaine abuse. |
| NCT00000332 ↗ | High Dose Nimodipine Treatment Adjunct - 1 | Completed | Washington D.C. Veterans Affairs Medical Center | Phase 2 | 1998-05-01 | The purpose of this study is to determine if nimodipine is more effective than placebo in reducing stimulated craving for cocaine in cocaine dependent individuals denied access to cocaine in inpatient unit. |
| NCT00000332 ↗ | High Dose Nimodipine Treatment Adjunct - 1 | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 1998-05-01 | The purpose of this study is to determine if nimodipine is more effective than placebo in reducing stimulated craving for cocaine in cocaine dependent individuals denied access to cocaine in inpatient unit. |
| NCT00000738 ↗ | Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1 | Completed | Glaxo Wellcome | Phase 1 | 1969-12-31 | PRIMARY: To assess the safety of nimodipine in the treatment of HIV-Associated Motor / Cognitive Complex (formerly AIDS dementia complex). To assess the systemic or central nervous system toxicities (e.g., rash, headache, gastrointestinal symptoms, nausea, dyspnea, muscle pain or cramp, acne) of nimodipine. SECONDARY: To assess the efficacy of nimodipine in stabilizing the progression of HIV-Associated Motor / Cognitive Complex by improvement in neuropsychological test performance, peripheral neuropathy, or other neurologic manifestations. HIV-infected patients may develop a condition known as HIV-Associated Motor / Cognitive Complex (also known as AIDS dementia complex) that causes damage to the nervous system, particularly the brain and spinal cord. Evidence exists that nimodipine protects nerve cells in culture from injury by HIV. Although nimodipine has been used in patients with other neurological problems, its safety and effectiveness in halting the progression of HIV-Associated Motor / Cognitive Complex is not yet known. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Nimodipine
Condition Name
Clinical Trial Locations for Nimodipine
Trials by Country
Clinical Trial Progress for Nimodipine
Clinical Trial Phase
Clinical Trial Sponsors for Nimodipine
Sponsor Name
